CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016

CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016
Published Jun 30, 2016
29 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016, provides in depth analysis on CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted pipeline therapeutics.

The report provides comprehensive information on the CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17)
- The report reviews CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics and enlists all their major and minor projects
- The report assesses CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy

  
Source:
Document ID
GMDHC0193TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Overview61
Therapeutics Development73
  CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Products under Development by Stage of Development71
  CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Products under Development by Therapy Area81
  CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Products under Development by Indication91
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Pipeline Products Glance101
  Early Stage Products101
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Products under Development by Companies111
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Products under Development by Universities/Institutes122
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Therapeutics Assessment145
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration161
  Assessment by Molecule Type172
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Companies Involved in Therapeutics Development191
  Sumitomo Dainippon Pharma Co., Ltd.191
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Drug Profiles206
  CNB-001 Drug Profile202
  KN-93 Drug Profile221
  Small Molecule 2 to Inhibit CaM Kinase for Malaria Drug Profile231
  Small Molecule to Inhibit CaM Kinase for Malaria Drug Profile241
  Small Molecules to Inhibit CaMKII for Undisclosed Indication Drug Profile251
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Dormant Projects261
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Discontinued Products271
Appendix282
  Methodology281
  Coverage281
  Secondary Research281
  Primary Research281
  Expert Panel Validation281
  Contact Us281
  Disclaimer291

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/CaM-Kinase-Ca2-Calmodulin-Dependent-Protein-Kinase-or-EC-2-7-11-17-Pipeline-Review-H1-2016-2088-16090>
  
APA:
Global Markets Direct - Market Research. (2016). CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/CaM-Kinase-Ca2-Calmodulin-Dependent-Protein-Kinase-or-EC-2-7-11-17-Pipeline-Review-H1-2016-2088-16090>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.